Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. Xu Q, Huang K, Meng X, Weng Y, et al. Clin Cancer Res 2023 Jul 21:CCR-23-0388. doi: 10.1158/1078-0432.CCR-23-0388.

Read + Share

Amedeo Smart

Independent Medical Education

Xu Q, Huang K, Meng X, Weng Y, et al. Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. Clin Cancer Res 2023 Jul 21:CCR-23-0388. doi: 10.1158/1078-0432.CCR-23-0388.
PMID: 37477938